Compare · ECOR vs TMDX
ECOR vs TMDX
Side-by-side comparison of electroCore Inc. (ECOR) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ECOR and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $3.25B, about 38.0x ECOR ($85.4M).
- Over the past year, ECOR is up 73.6% and TMDX is down 18.7% - ECOR leads by 92.3 points.
- ECOR has been more active in the news (7 items in the past 4 weeks vs 5 for TMDX).
- TMDX has more recent analyst coverage (19 ratings vs 2 for ECOR).
- Company
- electroCore Inc.
- TransMedics Group Inc.
- Price
- $9.39-2.59%
- $93.68+0.10%
- Market cap
- $85.4M
- $3.25B
- 1M return
- +52.81%
- +25.93%
- 1Y return
- +73.57%
- -18.71%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2019
- News (4w)
- 7
- 5
- Recent ratings
- 2
- 19
electroCore Inc.
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Rockaway, New Jersey.
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest ECOR
- CFO and Interim President Lev Joshua S. exercised 20,000 shares at a strike of $4.50 and sold $200,120 worth of shares (20,000 units at $10.01) (SEC Form 4)
- electroCore’s Truvaga® Named Best Luxury Biohacking & Longevity Brand in the USA by Luxury Lifestyle Awards
- Director Errico Thomas J. bought $49,272 worth of shares (5,000 units at $9.85), increasing direct ownership by 1% to 343,332 units (SEC Form 4)
- SEC Form 10-Q filed by electroCore Inc.
- electroCore Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- electroCore Announces Second Quarter 2026 Financial Results
- electroCore to Participate in Upcoming Investor Conferences
- electroCore to Announce Second Quarter June 30, 2026, Financial Results on Thursday, August 6, 2026
- SEC Form DEF 14A filed by electroCore Inc.
- New Review Examines Anatomical and Methodological Differences Between Auricular and Cervical Vagus Nerve Stimulation
Latest TMDX
- Director Tobin James R gifted 18,000 shares (SEC Form 4)
- SEC Form 10-Q filed by TransMedics Group Inc.
- TransMedics Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- TransMedics Reports Second Quarter 2026 Financial Results
- TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- TransMedics to Present at the Canaccord Genuity 46th Annual Growth Conference
- UBS initiated coverage on TransMedics Group with a new price target
- TransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026
- Officer Corcoran Nicholas was granted 11,727 shares, increasing direct ownership by 39% to 41,558 units (SEC Form 4)
- Chief Financial Officer Hernandez Gerardo was granted 17,246 shares, increasing direct ownership by 117% to 31,935 units (SEC Form 4)